Marginal Zone Lymphoma Pipeline

DelveInsight’s, “Marginal Zone Lymphoma Pipeline Insight, 2026” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Marginal Zone Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Marginal Zone Lymphoma Understanding

Marginal Zone Lymphoma Overview

Marginal zone lymphoma (MZL) is a rare, indolent mature B-cell malignancy that originates from post-germinal center memory B-cells and is among the most common subtypes of B-cell non-Hodgkin lymphoma. It can arise in both nodal and extranodal lymphoid tissues, particularly in the gastrointestinal tract, skin, and mucosa-associated lymphoid tissue. Diagnosis is based on tissue biopsy demonstrating characteristic clonal expansion of malignant B-cells with a distinct immunophenotypic profile. Although relatively uncommon, MZL has a favorable prognosis and high prevalence due to its slow disease progression and prolonged survival. It comprises three major clinical subtypes, extranodal, nodal, and splenic MZL, which share common biological features but differ in their clinical presentation, underlying molecular drivers, and treatment approaches.

Marginal zone lymphoma (MZL) comprises three distinct subtypes: extranodal MZL of mucosa-associated lymphoid tissue, splenic MZL, and nodal MZL. While these subtypes share common genetic abnormalities and frequent dysregulation of the NF-κB signaling pathway, they differ in their molecular alterations, including recurrent chromosomal translocations and mutations affecting key signaling pathways and regulatory genes. Advances in the understanding of MZL epidemiology, genetics, and disease biology have enhanced insights into its pathogenesis and continue to inform subtype-specific management strategies across different anatomical sites.

The diagnosis of marginal zone lymphoma (MZL) requires a comprehensive evaluation integrating clinical findings, histopathology, immunophenotyping, molecular testing, and imaging studies. According to international guidelines, an adequate excisional or core tissue biopsy is the cornerstone of diagnosis, as fine-needle aspiration alone is generally insufficient for accurate classification. Histopathological examination demonstrates infiltration by small- to medium-sized marginal zone B-cells, while immunohistochemistry is used to distinguish MZL from other indolent B-cell lymphomas. The characteristic immunophenotype includes CD20 positivity with negative expression of CD5, CD10, and cyclin D1, although rare exceptions may occur. Additional molecular and cytogenetic analyses may be performed to identify subtype-specific genetic abnormalities and exclude other lymphoid malignancies. Comprehensive staging includes complete blood counts, biochemical tests, bone marrow evaluation when clinically indicated, and contrast-enhanced CT or PET/CT imaging based on the disease subtype and clinical presentation. For extranodal MZL, site-specific investigations, such as endoscopy for gastric disease and testing for infectious agents including Helicobacter pylori, are also recommended to guide diagnosis and treatment.

The treatment landscape for marginal zone lymphoma (MZL) continues to evolve, although progress has been slower than that seen in other B-cell non-Hodgkin lymphomas due to the disease's rarity and the limited availability of dedicated clinical studies. Current treatment strategies are largely guided by single-arm trials, with few effective options available for patients with relapsed or refractory disease. Emerging therapies, including CD3×CD20 bispecific antibodies and antibody-drug conjugates, have demonstrated promising clinical activity, while circulating tumor DNA is gaining attention as a tool for risk stratification and treatment response monitoring. Given the biological and clinical heterogeneity of MZL subtypes, optimizing treatment requires a personalized, patient-centered approach that considers differences in disease characteristics, therapeutic response, and long-term outcomes.

"Marginal Zone Lymphoma Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Marginal Zone Lymphoma pipeline landscape is provided which includes the disease overview and Marginal Zone Lymphoma treatment guidelines. The assessment part of the report embraces, in depth Marginal Zone Lymphoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Marginal Zone Lymphoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Marginal Zone Lymphoma Pipeline Report Highlights

The Marginal Zone Lymphoma companies and academics are working to assess challenges and seek opportunities that could influence Marginal Zone Lymphoma R&D. The therapies under development are focused on novel approaches to treat/improve Marginal Zone Lymphoma.

Marginal Zone Lymphoma Emerging Drugs Analysis

This segment of the Marginal Zone Lymphoma report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Marginal Zone Lymphoma Emerging Drugs

MIL62: Beijing Mabworks Biotech Co., Ltd.

MIL62 is a novel third-generation, glycoengineered anti-CD20 monoclonal antibody developed by Beijing Mabworks Biotech for the treatment of B-cell malignancies, including relapsed/refractory marginal zone lymphoma (MZL). Designed with an afucosylated Fc region to enhance antibody-dependent cellular cytotoxicity (ADCC), MIL62 has demonstrated superior preclinical activity compared with earlier anti-CD20 antibodies. It is administered via intravenous infusion and is being evaluated in combination with lenalidomide for patients with relapsed/refractory MZL and follicular lymphoma. Currently, the drug is in Phase III stage of its development for the treatment of marginal zone lymphoma.

Odronextamab: Regeneron Pharmaceuticals

Odronextamab is a CD20×CD3 bispecific antibody developed by Regeneron Pharmaceuticals for the treatment of relapsed/refractory marginal zone lymphoma (MZL) and other B-cell non-Hodgkin lymphomas. The therapy redirects T cells to recognize and eliminate CD20-expressing malignant B cells, providing an off-the-shelf immunotherapy without the need for patient-specific cell manufacturing. It is administered by intravenous infusion using a step-up dosing regimen to mitigate cytokine release syndrome. Odronextamab is being evaluated in the Phase II ELM-2 trial for relapsed/refractory MZL, where it has demonstrated encouraging complete response rates and a manageable safety profile in heavily pretreated patients. While the drug is approved in the European Union for relapsed/refractory follicular lymphoma and diffuse large B-cell lymphoma after two or more prior systemic therapies, it remains investigational for MZL. Currently, the drug is in Phase III stage of its development for the treatment of relapsed/refractory marginal zone lymphoma.

EO2463: Enterome

EO2463 is a first-in-class, off-the-shelf OncoMimics™ peptide immunotherapy developed by Enterome for the treatment of indolent B-cell non-Hodgkin lymphomas, including follicular lymphoma and marginal zone lymphoma. The therapy comprises four synthetic, microbiome-derived peptides that mimic the B-cell lineage markers CD20, CD22, CD37, and CD268 (BAFF receptor), along with the helper peptide UCP2, to activate pre-existing CD8+ T cells and selectively eliminate malignant B cells while minimizing immune escape. EO2463 is administered subcutaneously and is being evaluated as both a monotherapy and in combination with rituximab and lenalidomide in the ongoing Phase I/II SIDNEY trial, where it has demonstrated a favorable safety profile and encouraging clinical activity in patients with indolent non-Hodgkin lymphoma.

LTZ-301: LTZ Therapeutics, Inc.

LTZ-301 is a first-in-class CD79b-targeted myeloid engager bispecific antibody developed by LTZ Therapeutics, Inc. for the treatment of relapsed/refractory B-cell non-Hodgkin lymphomas, including marginal zone lymphoma (MZL). The therapy redirects monocytes and macrophages to CD79b-positive B cells, promoting Fcγ receptor-independent antibody-dependent cellular phagocytosis (ADCP) and tumor cell depletion, representing a novel immunotherapeutic approach distinct from T-cell engagers. LTZ-301 is administered via intravenous infusion and is currently being evaluated as a single agent in a first-in-human Phase I, open-label, multicenter clinical trial in patients with MZL and other B-cell NHL subtypes.

Docirbrutinib: Carna Biosciences

Docirbrutinib is a highly selective, orally available, non-covalent pan-BTK inhibitor designed to target both wild-type and mutant Bruton's tyrosine kinase (BTK) for the treatment of chronic lymphocytic leukemia (CLL) and other B-cell malignancies. Unlike covalent BTK inhibitors, its activity is not dependent on the C481 binding site, enabling potent inhibition of resistance-associated BTK mutations, including C481S, as well as other mutations that may reduce the efficacy of currently approved covalent and non-covalent BTK inhibitors. This broad inhibitory profile positions docirbrutinib as a promising therapeutic option for patients with relapsed or refractory B-cell malignancies who have developed resistance to existing BTK-targeted therapies.  Currently, the drug is in Phase I stage of its development for the treatment of marginal zone lymphoma.

Further product details are provided in the report……..

Marginal Zone Lymphoma Drug Therapeutic Assessment

This segment of the report provides insights about the different Marginal Zone Lymphoma drugs segregated based on following parameters that define the scope of the report, such as:

Major Marginal Zone Lymphoma Players in Marginal Zone Lymphoma

There are approx. 50+ key companies which are developing the therapies for Marginal Zone Lymphoma. The companies which have their Marginal Zone Lymphoma drug candidates in the most advanced stage, i.e. Phase III include, Beijing Mabworks Biotech Co., Ltd.

Marginal Zone Lymphoma Clinical Trial Phases

DelveInsight’s report covers around 50+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Marginal Zone Lymphoma Drug Route of Administration

Marginal Zone Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Marginal Zone Lymphoma Product Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Marginal Zone Lymphoma Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Marginal Zone Lymphoma Clinical Trial Activities

The Marginal Zone Lymphoma pipeline report provides insights into different Marginal Zone Lymphoma clinical trials within Phase III, II, I, preclinical and discovery stage. It also analyses Marginal Zone Lymphoma therapeutic drugs key players involved in developing key drugs.

Marginal Zone Lymphoma Pipeline Development Activities

The Marginal Zone Lymphoma clinical Trial analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Marginal Zone Lymphoma drugs.

Marginal Zone Lymphoma Pipeline Report Insights

• Marginal Zone Lymphoma Pipeline Analysis
• Marginal Zone Lymphoma  Therapeutic Assessment
• Marginal Zone Lymphoma Unmet Needs
• Impact of Marginal Zone Lymphoma Drugs

Marginal Zone Lymphoma Pipeline Report Assessment

• Marginal Zone Lymphoma Pipeline Product Profiles
• Marginal Zone Lymphoma Therapeutic Assessment
• Marginal Zone Lymphoma Pipeline Assessment
• Marginal Zone Lymphoma Inactive drugs assessment
• Marginal Zone Lymphoma Market Unmet Needs

Key Questions Answered In The Marginal Zone Lymphoma Pipeline Report:

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Marginal Zone Lymphoma drugs?
• How many Marginal Zone Lymphoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Marginal Zone Lymphoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Marginal Zone Lymphoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Marginal Zone Lymphoma and their status?
• What are the key designations that have been granted to the emerging drugs?

Marginal Zone Lymphoma Key Players

• Enterome
• Beijing Mabworks Biotech Co., Ltd.
• Regeneron Pharmaceuticals
• LTZ Therapeutics, Inc.
• Carna Biosciences, Inc.
• Eli Lilly and Company
• Newave Pharmaceutical Inc
• Merck
• BeOne Medicines
• CRISPR Therapeutics AG
• ModeX Therapeutics, An OPKO Health Company
• Nurix Therapeutics, Inc.
• Sana Biotechnology
• Recursion Pharmaceuticals
• Schrödinger
• Verismo Therapeutics
• Ascentage Pharma Group Inc.
• Accutar Biotechnology Inc

Marginal Zone Lymphoma Key Products

• EO2463
• MIL62
• Odronextamab
• LTZ-301
• Docirbrutinib
• LY4152199
• LOXO-338
• LP-168
• Nemtabrutinib
• BGB-21447
• CTX112
• MDX2003
• NX-2127
• SC262
• SC291
• REC-3565
• SGR-1505
• SynKIR-310
• APG-3288
• AC676